All In Biotech

Drug Trial Radar · NCT06425224

Effectiveness and Safety of TENS Therapy for Premature Ejaculation

Effectiveness and Safety of Transcutaneous Posterior Tibial Nerve Stimulation Therapy for the Management of Patients With Premature Ejaculation. Phase III Clinical Trial

Last checked: Nov 20, 2026Latest source record: May 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

129

Planned (sponsor's estimate)

Start

Jun 15, 2022

Primary completion

Jun 2025

Study completion Jun 2025

Sponsor

Lead sponsor
Boston Medical GroupIndustry
Sponsor type
Industry
First posted
May 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 62 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to evaluate the effectiveness and safety of transcutaneous posterior tibial nerve stimulation therapy in patients with premature ejaculation. The main question to answer is: Can the effectiveness and safety of transcutaneous electrostimulation of the posterior tibial nerve alone and combined with standard pharmacological treatment be evaluated in men with lifelong premature ejaculation, compared to standard pharmacological treatment with dapoxetine? Patients will: Be randomized in acontrolled clinical trial. Patients with a diagnosis of premature ejaculation who attend Boston Medical Group clinics in Mexico City will be included. Be assigned by randomization to one of three treatment groups: * Group 1: Tens therapy + dapoxetine placebo on demand. * Group 2: Standard treatment (dapoxetine 30 mg as needed) + placebo therapy. * Group 3: Tens therapy + standard treatment (dapoxetine 30 mg as needed).

Conditions

  • Premature Ejaculation
  • Sex Disorder
  • TEN

Interventions

  • Tens therapyDevice

    There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows: 1\. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia. The second reference electrode (anode - black) is attached to the calcaneus. The equipment must previously be programmed under the following parameters: Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation.

  • Dapoxetine placeboDrug

    Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.

  • Standard treatment (dapoxetine 30 mg as needed)Drug

    Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study

  • Placebo therapyDevice

    In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in intravaginal latency timeTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Boston Medical Group

    Mexico City, Mexico · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.